Pheton Holdings Ltd Class A Ordinary Shares
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Pheton Holdings Ltd Pheton Holdings Ltd is a holding company principally engaged in the provision of healthcare solutions through its wholly-owned subsidiary Beijing Feitian Zhaoye Technology Co., Ltd.; the company develops and commercializes brachytherapy treatment planning systems, including its proprietary FTTPS software designed for radioactive particle implantation to treat malignant tumors by determining target volumes, prescription doses, and organ-at-risk protections; and offers related medical auxiliary supplies such as seed implant needles, computer workstations, and patient positioning devices. Founded in 1998 and headquartered in Beijing, China, Pheton Holdings Ltd operates primarily in the medical devices segment of the healthcare industry, targeting oncology practices and cancer treatment facilities with a focus on improving the efficiency, accuracy, and safety of radiation therapy. In August 2025, the company entered into a Stock Purchase Agreement to acquire a 51% stake in iTonic Corporation, a home health technology provider integrating medication dispensing, supply chain management, virtual care, and patient monitoring, by issuing 4 million Class A ordinary shares and warrants for 3 million additional shares subject to performance milestones; on the same period, it agreed to purchase a 30% stake in Geri-Safe Ltd. for $3 million to bolster medical device innovation; and signed a five-year Advisory Services Agreement with Comane International Group Ltd., issuing warrants for up to 4 million Class A shares to support mergers, acquisitions, and corporate development strategies. Pheton Holdings Ltd completed its initial public offering on the Nasdaq Capital Market under the ticker PTHL in September 2024, raising gross proceeds of $9 million for research, development, market expansion, and operational enhancements. The company holds a significant market share in China's brachytherapy TPS installations and remains a subsidiary of ZJW (BVI) Ltd.
Contrasting Pheton (NASDAQ:PTHL) and Oncology Institute (NASDAQ:TOI)
Nasdaq Moves to Block Risky IPOs as Microcap Chaos Draws Regulator Fire
Pheton Holdings Ltd Announces Closing of Share Acquisition with iTonic Corporation
Pheton Holdings Ltd Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency
Pheton Holdings Ltd Issues Statements Addressing Recent Market Activity and Misleading Rumors
U.S. IPO Weekly Recap: 2 APAC Microcaps Go Public In Short Labor Day Week As The Pipeline Grows
Pheton Holdings Ltd Announces Closing of Initial Public Offering
Pheton Holdings Ltd Announces Pricing of Initial Public Offering
U.S. IPO Weekly Recap: Birkenstock Missteps In Public Debut
Pheton Holdings Pursues U.S. Micro-IPO